- Home
- RDCM vs NGEN Comparison
RDCM vs NGEN Comparison
Compare RDCM & NGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RDCM | NGEN |
|---|---|---|
| Founded | 1985 | 2017 |
| Country | Israel | Canada |
| Employees | N/A | N/A |
| Industry | Computer peripheral equipment | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 170.6M | 200.0M |
| IPO Year | 1999 | 2018 |
Fundamental Metrics
Financial Performance| Metric | RDCM | NGEN |
|---|---|---|
| Price | $9.87 | $2.18 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $18.00 | $18.00 |
| AVG Volume (30 Days) | 134.4K | ★ 579.5K |
| Earning Date | 05-13-2026 | 04-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $11.50 | N/A |
| Revenue Next Year | $9.74 | N/A |
| P/E Ratio | $16.35 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.40 | $1.58 |
| 52 Week High | $16.74 | $5.93 |
Technical Indicators
Market Signals| Indicator | RDCM | NGEN |
|---|---|---|
| Relative Strength Index (RSI) | 33.20 | 59.87 |
| Support Level | $9.40 | $1.62 |
| Resistance Level | $10.79 | $2.32 |
| Average True Range (ATR) | 0.26 | 0.15 |
| MACD | 0.08 | 0.03 |
| Stochastic Oscillator | 20.86 | 70.83 |
Price Performance
Historical ComparisonAbout RDCM Radcom Ltd.
Radcom Ltd Ltd is engaged in providing network intelligence, 5G ready cloud-native, network intelligence solutions for telecom operators transitioning to 5G. The company has a network intelligence solution for 5G namely Radcom ACE. Its products consist of Radcom Network Visibility, Radcom Service Assurance, and Radcom Network Insights. It has offices in Israel, the United States, Brazil, and India. Key revenue is derived from sales in North America.
About NGEN NervGen Pharma Corp. Common stock
NervGen Pharma Corp is a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury and other traumatic and neurologic conditions. The Company's principal business activity is the discovery, development and commercialization of neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions. NervGen's initial target indication is SCI. The company's pipeline products include NVG-291 and NVG-300.